These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 17323187

  • 21. Inhibitory effect of the selective serotonin 5-HT₃ receptor antagonist ramosetron on duodenal acidification-induced gastric hypersensitivity in rats.
    Nakata-Fukuda M, Hirata T, Keto Y, Yamano M, Yokoyama T, Uchiyama Y.
    Eur J Pharmacol; 2014 May 15; 731():88-92. PubMed ID: 24632457
    [Abstract] [Full Text] [Related]

  • 22. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
    Moskwa A, Boznańska P.
    Wiad Lek; 2007 May 15; 60(7-8):371-6. PubMed ID: 18175558
    [Abstract] [Full Text] [Related]

  • 23. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study.
    Fukudo S, Kinoshita Y, Okumura T, Ida M, Hayashi K, Akiho H, Nakashima Y, Haruma K.
    J Gastroenterol; 2016 Sep 15; 51(9):874-82. PubMed ID: 26800997
    [Abstract] [Full Text] [Related]

  • 24. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).
    Min YW, Rhee PL.
    Therap Adv Gastroenterol; 2015 May 15; 8(3):136-42. PubMed ID: 25949526
    [Abstract] [Full Text] [Related]

  • 25. The selective 5-hydroxytryptamine 1A antagonist, AZD7371 [3(R)-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (R,R)-tartrate monohydrate] (robalzotan tartrate monohydrate), inhibits visceral pain-related visceromotor, but not autonomic cardiovascular, responses to colorectal distension in rats.
    Lindström E, Ravnefjord A, Brusberg M, Hjorth S, Larsson H, Martinez V.
    J Pharmacol Exp Ther; 2009 Jun 15; 329(3):1048-55. PubMed ID: 19325032
    [Abstract] [Full Text] [Related]

  • 26. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome.
    Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D.
    Digestion; 2008 Jun 15; 77(3-4):225-35. PubMed ID: 18667823
    [Abstract] [Full Text] [Related]

  • 27. Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice.
    Barone FC, Barton ME, White RF, Legos JJ, Kikkawa H, Shimamura M, Kuratani K, Kinoshita M.
    Pharmacology; 2008 Jun 15; 81(1):11-7. PubMed ID: 17726343
    [Abstract] [Full Text] [Related]

  • 28. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome.
    Zou BC, Dong L, Wang Y, Wang SH, Cao MB.
    Chin Med J (Engl); 2007 Dec 05; 120(23):2069-74. PubMed ID: 18167178
    [Abstract] [Full Text] [Related]

  • 29. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG.
    Am J Gastroenterol; 2007 Aug 05; 102(8):1709-19. PubMed ID: 17509028
    [Abstract] [Full Text] [Related]

  • 30. Effect of YNS-15P, a new alpha-2 adrenoceptor antagonist, on stress-stimulated colonic propulsion in rats.
    Yamamoto O, Niida H, Tajima K, Shirouchi Y, Kyotani Y, Ueda F, Kise M, Kimura K.
    J Pharmacol Exp Ther; 1998 Nov 05; 287(2):691-6. PubMed ID: 9808698
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R, Nikfar S, Abdollahi M.
    Clin Ther; 2008 May 05; 30(5):884-901. PubMed ID: 18555935
    [Abstract] [Full Text] [Related]

  • 33. Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1.
    Shiotani A, Kusunoki H, Ishii M, Imamura H, Manabe N, Kamada T, Hata J, Merchant JL, Haruma K.
    Neurogastroenterol Motil; 2015 Jan 05; 27(1):82-91. PubMed ID: 25428414
    [Abstract] [Full Text] [Related]

  • 34. Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.
    Chey WD, Cash BD.
    Expert Opin Investig Drugs; 2005 Feb 05; 14(2):185-93. PubMed ID: 15757394
    [Abstract] [Full Text] [Related]

  • 35. Role of the serotonin3 receptor in stress-induced defecation.
    Miyata K, Kamato T, Nishida A, Ito H, Yuki H, Yamano M, Tsutsumi R, Katsuyama Y, Honda K.
    J Pharmacol Exp Ther; 1992 Apr 05; 261(1):297-303. PubMed ID: 1560375
    [Abstract] [Full Text] [Related]

  • 36. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?
    Sweetser S, Camilleri M, Linker Nord SJ, Burton DD, Castenada L, Croop R, Tong G, Dockens R, Zinsmeister AR.
    Am J Physiol Gastrointest Liver Physiol; 2009 Jun 05; 296(6):G1299-306. PubMed ID: 19342506
    [Abstract] [Full Text] [Related]

  • 37. Selective corticotropin-releasing factor 1 receptor antagonist E2508 reduces restraint stress-induced defecation and visceral pain in rat models.
    Taguchi R, Shikata K, Furuya Y, Hirakawa T, Ino M, Shin K, Shibata H.
    Psychoneuroendocrinology; 2017 Jan 05; 75():110-115. PubMed ID: 27810704
    [Abstract] [Full Text] [Related]

  • 38. 5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome.
    Kishibayashi N, Miwa Y, Hayashi H, Ishii A, Ichikawa S, Nonaka H, Yokoyama T, Suzuki F.
    J Med Chem; 1993 Oct 29; 36(22):3286-92. PubMed ID: 8230119
    [Abstract] [Full Text] [Related]

  • 39. Melatonin attenuates stress-induced defecation: lesson from a rat model of stress-induced gut dysfunction.
    Song GH, Gwee KA, Moochhala SM, Ho KY.
    Neurogastroenterol Motil; 2005 Oct 29; 17(5):744-50. PubMed ID: 16185314
    [Abstract] [Full Text] [Related]

  • 40. Effectiveness of probiotics in the treatment of irritable bowel syndrome.
    Wilhelm SM, Brubaker CM, Varcak EA, Kale-Pradhan PB.
    Pharmacotherapy; 2008 Apr 29; 28(4):496-505. PubMed ID: 18363533
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.